B
y leveraging a cell's built-in ability to squelch individual genes, a pair of scientists has invented a quick and relatively inexpensive method for finding weaknesses in cancer cells. The approach uses a cell culture system that screens thousands of genes simultaneously for their effects on the growth and survival of tumor cells.
In two reports in Science this February, Gregory Hannon, Ph.D. , and Stephen Elledge, Ph.D. , describe the system and identify dozens of potential new gene targets for fi ghting colon and breast cancer. The researchers hope that their approach will lead to new drugs that selectively kill cancer cells.
"We're fi nding all kinds of potential new targets in our gene lists that are specifi c for killing cancer cells but don't seem to affect normal cells," said Elledge, a Howard Hughes Medical Institute investigator at Harvard Medical School in Boston.
Better still, the technique is simple enough that "any investigator can do it without millions of dollars of robotics and other high-tech equipment," said Hannon, a Howard Hughes Medical Institute investigator at Cold Spring Harbor Laboratory in New York.
The method exploits a powerful cellular mechanism called RNA interference (RNAi). Discovered just a decade ago, RNAi probably evolved to help cells fight viruses. The cellular machinery involved fi rst identifi es short segments of suspicious-looking RNA and then destroys all identical copies of that RNA. The result: None of the protein that the RNA encodes gets made.
Although RNAi prevents viruses from replicating inside cells, scientists discovered that they can exploit the process to squelch individual gene products. To do so, they introduce a short segment of RNA that looks like one of the cell's normal genes. The RNAi machinery grinds into action and shuts down production of the protein made from that gene. N E W S mechanism. They've now made short hairpin RNAs that can silence every gene in the human and mouse genomes.
For their experiments reported in Science, the pair fi rst identifi ed 3,000 genes important in cell signaling, growth, and other essential processes. Next, they inserted a genetic code for short hairpin RNAs that target these genes into retroviruses. Then they infected dishes of normal and tumor cells with the retroviruses, which added instructions to each cell's genome telling it to produce a short hairpin RNA. These short RNAs then triggered the RNAi mechanism. In effect, each virus in the experiment stopped production of one protein in one cell.
In the past, researchers used this method to study the effects of turning off one particular gene. But to study the effects of thousands of genes, researchers had to run thousands of separate experiments with thousands of plates of cells.
Instead, Hannon and Elledge developed a method to track a diverse pool of short hairpin RNAs in parallel. They call it "barcoding": Every short hairpin RNA molecule that they make carries a unique genetic tag. This tag lets the researchers track the effect of thousands of the RNAs in one pool of cells in one lab dish.
"We get a mixture of cells where each cell has one of these genes knocked down," Hannon said.
If RNAi knocks down a gene important for cell growth and survival, the cell fails to thrive or dies. At the end of the experiment, then, the researchers recover only small amounts of the short hairpin RNA associated with that gene. This fi nding suggests to the researchers that the gene is a potential weakness for the cell.
After running many such experiments on normal, breast, and colon cancer cells, the team found dozens of genes that, when eliminated, hinder cancer cells but don't seem to harm normal cells.
"We're examining as many genes as we can, eventually every gene in the genome, to fi gure out which ones are deleterious to tumor cells. And when you screen in this unbiased way, you start fi nding things you couldn't have predicted," Elledge said. The next stage of the project will screen all known genes for more weaknesses.
Complementary Approaches
Eric Lander, Ph.D., a genomics researcher at the Broad Institute in Cambridge, Mass., says that functional RNAi screens such as those run by Hannon and Elledge complement the government-funded effort to sequence the genomes of various types of cancers. That project, called the Cancer Genome Atlas, is funded by the National Cancer Institute and the National Human Genome Research Institute. It is now in its pilot phase, estimated to cost $150 million over 3 years. The pilot phase is focused on fi nding key cancer-causing mutations in hundreds of samples of lung, ovarian, and brain tumors.
Hannon and Elledge criticized the Cancer Genome Atlas Project at its inception in 2005, recommending in a letter to Science that the project be delayed until the cost of cell sequencing fell substantially. In the letter they also argue for government investment in RNAi screening. More recently, Elledge said, "If you take all the sequences that will come out of the extremely expensive cancer genome sequencing effort, you're not going to know which ones are important until you do functional analysis. We're already doing that functional analysis."
Lander, who cochaired the NCI committee that recommended the Cancer Genome Atlas Project, also leads the Broad Institute, which is one of three genome sequencing centers involved in the effort. He counters that the sequencing project has already found "bunches of new genes" involved in glioblastoma, the most common form of brain cancer. A report describing these early results is in progress.
Lander praised the value of large-scale RNAi screens and said such screening, when added to the sequencing data, creates a "pincher movement" toward promising gene targets for new drugs.
"They're two sides of the same coin," he said of the two approaches. Sequencing highlights genes that are mutated in patients, whereas the RNAi screen pinpoints genes that kill cancer cells. But the real payoff will come, Lander said, when researchers combine datasets. If both approaches highlight the same gene, then drug developers will have a hot target to aim for.
Researchers at the Dana-Farber Cancer Institute used such a dual-headed approach last year. In a report in Cell , a team led by William Hahn, M.D., Ph.D., combined sequencing and RNAi screening to highlight a gene called IKBKE as an important breast cancer oncogene. The gene, which codes for a signaling protein in the kinase family, is overabundant in many breast cancers. And knocking it down with RNAi kills tumor cells. "It's a beautiful example of combining the two techniques," Lander said. "The real power will come from this combination." Lander envisions a comprehensive library of mutation and RNAi screening data as a basic reference tool for cancer researchers of the near future.
To that end, Hannon and Elledge are making their library of short hairpin RNAs available to researchers through a company called Open Biosystems, based in Huntsville, Ala. "There's a dual goal," Hannon said. "Not only can our own science benefi t, but others can use the RNAi screening techniques now, too." 
